:{unav)

2016 International Journal of Pharmaceutical Sciences and Research  
Co-crystals consists of API and a stoichiometric amount of a pharmaceutically acceptable co-crystal former. Pharmaceutical Co-crystals are nonionic supramolecular complexes and can be used to address physical property issues such as solubility, stability and bioavailability in pharmaceutical development without changing the chemical composition of the API. Cocrystal is a crystalline entity formed by two different or more molecular entities where the intermolecular interactions are weak forces
more » ... s are weak forces like hydrogen bonding and π-π stacking. Super porous systems, biodegradable hydrogel systems. Co-crystallization alters the molecular interactions and composition of pharmaceutical materials, and is considered better alternative to optimize drug properties. Co-crystals offer a different pathway, where any API regardless of acidic, basic, or ionizable groups, could potentially be co crystallized. This aspect also helps complement existing methods by reintroducing molecules that had limited pharmaceutical profiles based on their nonionizable functional groups. The article gives a brief review on the co-crystallization, its difference from other states and its importance as an alternative over slat formation. The review also highlights the current FDA notice on Guidance on co-crystallization, the various methods of preparing cocrystals and their characterization. The article also gives a gist of the various cocrystals which have been worked on thus highlighting their importance in current trend for enhancing various physical, chemical and pharmacological properties. QUICK RESPONSE CODE
doi:10.13040/ijpsr.0975-8232.5(9).3566-76 fatcat:kqryao5ck5eyznwb5dlux4iapi